Positron emission tomography combined with serum biomarkers detects fibrotic MASH
Metabolic dysfunction-associated steatohepatitis (MASH) is a rising global disease signaling the urgent need for non-invasive tests (NITs). Recent work demonstrated that dynamic <sup>18</sup>F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) imaging can identify MASH by measuring liver glucose transport rate, K<sub>1</sub>, and liver CT attenuation. By combining dynamic PET/CT with the serum-based fibrosis-4 (FIB-4) test, we were able to better distinguish clinical MASH from fibrotic subtypes, enabling determination of the core tenets of MASH: steatosis, inflammation, and fibrosis. Future studies using FDG-PET technology can further enable concomitant prediction of MASH severity and extrahepatic comorbidities such as cardiovascular disease.
Authors
- Karen Matsukuma (ORCID: https://orcid.org/0000-0003-2268-1815)
- Souvik Sarkar (ORCID: https://orcid.org/0000-0002-9358-4257)
- Connie Chan
- Victoria Lyo (ORCID: https://orcid.org/0000-0003-3139-7365)
- Sean Romeo
- Guobao Wang (ORCID: https://orcid.org/0000-0001-6526-1533)
- Michael T. Corwin (ORCID: https://orcid.org/0000-0001-8930-9765)
- Shuai Chen (ORCID: https://orcid.org/0000-0003-0519-816X)
Institutions
- University of California System (US)
- University of California, Davis (US)
Publication Details
- Journal
- Scientific Reports
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1038/s41598-024-72655-x
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- University of California, Davis
- National Institute of Diabetes and Digestive and Kidney Diseases